200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 159351-69-6
159351-69-6 | Rapamycin, 42-O-(2-hydroxyethyl)-
CAS No: 159351-69-6 Catalog No: AG001QMG MDL No:MFCD00929329
Product Description
Catalog Number:
AG001QMG
Chemical Name:
Rapamycin, 42-O-(2-hydroxyethyl)-
CAS Number:
159351-69-6
Molecular Formula:
C53H83NO14
Molecular Weight:
958.2244
MDL Number:
MFCD00929329
SMILES:
OCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)C(=CC=CC=C[C@H](C[C@H](C(=O)[C@@H]([C@@H](C(=C[C@H](C(=O)C1)C)C)O)OC)C)C)C)C
Literature
| Title | Journal |
|---|---|
| Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. | Toxicology in vitro : an international journal published in association with BIBRA 20180201 |
| Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. | Toxicology and applied pharmacology 20170901 |
| Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo. | Environmental toxicology 20170701 |
| The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. | Oncotarget 20170131 |
| OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. | International journal of cancer 20161101 |
| Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. | Oncotarget 20160906 |
| Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20160301 |
| Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. | Cancer chemotherapy and pharmacology 20160101 |
| Better Together: Targeted Combination Therapies in Breast Cancer. | Seminars in oncology 20151201 |
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. | The New England journal of medicine 20151105 |
| Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. | Journal of the National Cancer Institute 20151001 |
| A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. | International journal of cancer 20150615 |
| Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. | Oncotarget 20150201 |
| mTOR inhibition improves immune function in the elderly. | Science translational medicine 20141224 |
| An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis. | Clinical nephrology 20141201 |
| A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. | Nature chemical biology 20141201 |
| P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20140615 |
| A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. | European journal of cancer (Oxford, England : 1990) 20140301 |
| Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. | Cancer chemotherapy and pharmacology 20130501 |
| Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. | European journal of pharmacology 20121205 |
| A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. | Investigational new drugs 20121201 |
| Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. | Cancer letters 20121101 |
| UV-visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant-containing dissolution media: a useful approach based on solid-phase extraction. | Journal of pharmaceutical and biomedical analysis 20121101 |
| Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. | Nephrology (Carlton, Vic.) 20121101 |
| Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. | Carcinogenesis 20121101 |
| NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. | Expert opinion on investigational drugs 20121101 |
| Towards excellence in revascularization for left main coronary artery disease. | Current opinion in cardiology 20121101 |
| Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. | Cancer chemotherapy and pharmacology 20121101 |
| A drug safety evaluation of everolimus in kidney transplantation. | Expert opinion on drug safety 20121101 |
| Endothelial progenitor cell response to antiproliferative drug exposure. | Atherosclerosis 20121101 |
| Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20121101 |
| Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. | Cancer 20121015 |
| A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. | Transplantation 20121015 |
| Genome sequencing identifies a basis for everolimus sensitivity. | Science (New York, N.Y.) 20121012 |
| The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20121001 |
| Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. | Annals of oncology : official journal of the European Society for Medical Oncology 20121001 |
| Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. | Cancer letters 20121001 |
| Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20121001 |
| Novel agents in Hodgkin lymphoma. | Current oncology reports 20121001 |
| Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. | Journal of molecular endocrinology 20121001 |
| Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. | Endocrine-related cancer 20121001 |
| Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. | Transplant international : official journal of the European Society for Organ Transplantation 20121001 |
| Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. | Japanese journal of clinical oncology 20121001 |
| Everolimus for the treatment of pancreatic neuroendocrine tumors. | Expert opinion on pharmacotherapy 20121001 |
| FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. | Cancer research 20121001 |
| A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121001 |
| Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121001 |
| Everolimus in pediatric transplantation. | Current opinion in organ transplantation 20121001 |
| Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. | Analytical and bioanalytical chemistry 20121001 |
| Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. | Endocrine-related cancer 20121001 |
| Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121001 |
| Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry. | The Journal of invasive cardiology 20121001 |
| Late stent thrombosis of a second-generation drug- eluting stent. | The Journal of invasive cardiology 20121001 |
| Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20121001 |
| Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. | Transplantation 20120927 |
| Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. | International journal of pharmaceutics 20120915 |
| Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). | The American journal of cardiology 20120915 |
| Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. | American journal of physiology. Renal physiology 20120915 |
| K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. | Cancer letters 20120901 |
| Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status. | Clinical genitourinary cancer 20120901 |
| Case of complete response to everolimus for metastatic renal cell carcinoma. | International journal of urology : official journal of the Japanese Urological Association 20120901 |
| Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. | Cancer science 20120901 |
| Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120901 |
| Inhibition of mTOR in carcinoid tumors. | Targeted oncology 20120901 |
| Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. | Acta oncologica (Stockholm, Sweden) 20120901 |
| Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. | Targeted oncology 20120901 |
| Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors. | The Annals of pharmacotherapy 20120901 |
| Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin. | Transplantation proceedings 20120901 |
| Everolimus and enteric-coated mycophenolate sodium ab initio after liver transplantation: midterm results. | Transplantation proceedings 20120901 |
| Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells. | British journal of cancer 20120821 |
| Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. | Fundamental & clinical pharmacology 20120801 |
| Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. | Investigational new drugs 20120801 |
| Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. | The international journal of cardiovascular imaging 20120801 |
| Connective tissue growth factor (CTGF/CCN2): a protagonist in cardiac allograft vasculopathy development? | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20120801 |
| Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120801 |
| Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. | International journal of oncology 20120801 |
| Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. | Endocrine-related cancer 20120801 |
| Xience side branch access stent for treatment of bifurcation coronary disease: a review of preclinical data. | Journal of interventional cardiology 20120801 |
| Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. | Cancer chemotherapy and pharmacology 20120801 |
| Flow patterns at stented coronary bifurcations: computational fluid dynamics analysis. | Circulation. Cardiovascular interventions 20120801 |
| Pregnancy in a kidney transplant patient treated with everolimus. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20120801 |
| Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? | The oncologist 20120801 |
| Targeting angiogenesis in metastatic breast cancer. | The oncologist 20120801 |
| The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial. | Anticancer research 20120801 |
| In silico prediction for the investigation of comedication interferences in quantitative LC-MS detection in the SRM mode. | Bioanalysis 20120801 |
| Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. | Journal of the American College of Cardiology 20120731 |
| Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. | Journal of cellular and molecular medicine 20120701 |
| Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. | Clinical endocrinology 20120701 |
| Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120701 |
| A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. | Haematologica 20120701 |
| Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. | European journal of cancer (Oxford, England : 1990) 20120701 |
| Effects of the combination of RAD001 and docetaxel on breast cancer stem cells. | European journal of cancer (Oxford, England : 1990) 20120701 |
| Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. | The American journal of cardiology 20120701 |
| Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. | European journal of cancer (Oxford, England : 1990) 20120701 |
| A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120701 |
| Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20120701 |
| Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. | Clinical pharmacokinetics 20120701 |
| A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. | Cancer chemotherapy and pharmacology 20120701 |
| Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. | Pediatrics 20120701 |
| [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20120701 |
| Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. | Annals of oncology : official journal of the European Society for Medical Oncology 20120701 |
| Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. | Anticancer research 20120701 |
| mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. | Science translational medicine 20120620 |
| Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. | Transplantation 20120615 |
| Long-term clinical and angiographic outcome after treatment of chronic total occlusion with everolimus or sirolimus eluting stents. | International journal of cardiology 20120614 |
| Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. | Circulation 20120612 |
| Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy. | Investigational new drugs 20120601 |
| Everolimus-related organizing pneumonia: a report establishing causality. | Investigational new drugs 20120601 |
| 40-O -[2-Hydroxyethyl]rapamycin modulates human dendritic cell function during exposure to Aspergillus fumigatus. | Journal of basic microbiology 20120601 |
| Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120601 |
| Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20120601 |
| Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20120601 |
| Post-transcriptional modulation of C/EBPα prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells. | Leukemia research 20120601 |
| Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. | Clinical research in cardiology : official journal of the German Cardiac Society 20120601 |
| Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? | Current oncology reports 20120601 |
| Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice. | Atherosclerosis 20120601 |
| Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. | Molecular cancer therapeutics 20120601 |
| Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? | European heart journal 20120601 |
| Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. | Molecular diagnosis & therapy 20120601 |
| A further step towards vascular reparative therapy. | European heart journal 20120601 |
| New targeted agents in gastroenteropancreatic neuroendocrine tumors. | Targeted oncology 20120601 |
| Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients. | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20120601 |
| Everolimus-induced lymphedema in a renal transplant recipient: a case report. | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20120601 |
| Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120601 |
| [Renal carcinoma: point on treatment of brain metastasis]. | Bulletin du cancer 20120601 |
| Targeting mTOR in mantle cell lymphoma: current and future directions. | Best practice & research. Clinical haematology 20120601 |
| Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors. | Lymphatic research and biology 20120601 |
| Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. | JACC. Cardiovascular interventions 20120601 |
| The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. | Future oncology (London, England) 20120601 |
| Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention. | Annals of the Academy of Medicine, Singapore 20120601 |
| Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20120515 |
| Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. | Antiviral chemistry & chemotherapy 20120514 |
| Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120501 |
| A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. | Cancer 20120501 |
| Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. | Oncology reports 20120501 |
| Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120501 |
| Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. | The American journal of cardiology 20120501 |
| Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. | Arteriosclerosis, thrombosis, and vascular biology 20120501 |
| Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120501 |
| Limus is not limus--a proposal to adjust terminology in the context of drug-eluting stents. | Journal of cardiovascular pharmacology 20120501 |
| Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. | Clinical and experimental immunology 20120501 |
| Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. | Transplant international : official journal of the European Society for Organ Transplantation 20120501 |
| Objective versus subjective guidance of (bioabsorbable) stent implantation: the saga continues. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120501 |
| Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120501 |
| Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience. | Transplantation proceedings 20120501 |
| Clinical experience of tacrolimus with everolimus in heart transplantation. | Transplantation proceedings 20120501 |
| Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. | Anticancer research 20120501 |
| The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. | American heart journal 20120501 |
| Late subcapsular lymphocele in a kidney graft. | Transplantation 20120427 |
| The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. | Blood 20120426 |
| Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. | Circulation 20120424 |
| Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. | British journal of cancer 20120424 |
| The struggle for energy in podocytes leads to nephrotic syndrome. | Cell cycle (Georgetown, Tex.) 20120415 |
| Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. | Journal of the American College of Cardiology 20120410 |
| A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. | Journal of the American College of Cardiology 20120410 |
| Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. | The international journal of cardiovascular imaging 20120401 |
| Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. | The international journal of cardiovascular imaging 20120401 |
| Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street? | Cancer 20120401 |
| Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. | Cancer 20120401 |
| Dynamic contrast-enhanced micro-CT on mice with mammary carcinoma for the assessment of antiangiogenic therapy response. | European radiology 20120401 |
| Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. | Journal of cancer research and clinical oncology 20120401 |
| Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® system. | Scandinavian journal of clinical and laboratory investigation 20120401 |
| Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20120401 |
| Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. | European urology 20120401 |
| Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120401 |
| Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood. | Therapeutic drug monitoring 20120401 |
| New strategies for advanced neuroendocrine tumors in the era of targeted therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120401 |
| Everolimus: preventing organ rejection in adult kidney transplant recipients. | Expert opinion on pharmacotherapy 20120401 |
| Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. | Circulation. Cardiovascular interventions 20120401 |
| Everolimus: targeted therapy on the horizon for the treatment of breast cancer. | Pharmacotherapy 20120401 |
| Successful sealing of a coronary artery perforation with a mesh-covered stent. | The Journal of invasive cardiology 20120401 |
| Breakthroughs in myeloproliferative neoplasms. | Hematology (Amsterdam, Netherlands) 20120401 |
| The prequel: defining prognostically important criteria in the periprocedural PCI troponin saga. | Circulation. Cardiovascular interventions 20120401 |
| Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process. | JACC. Cardiovascular interventions 20120401 |
| DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population. | American heart journal 20120401 |
| ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). | American heart journal 20120401 |
| Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. | Clinical advances in hematology & oncology : H&O 20120401 |
| Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. | Journal of the American College of Cardiology 20120320 |
| Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. | Transplantation 20120315 |
| PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). | Circulation 20120313 |
| Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. | British journal of cancer 20120313 |
| Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. | The New England journal of medicine 20120308 |
| Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. | Circulation 20120306 |
| Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor. | Molecular and cellular endocrinology 20120305 |
| Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. | The international journal of cardiovascular imaging 20120301 |
| Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography. | The international journal of cardiovascular imaging 20120301 |
| Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. | The international journal of cardiovascular imaging 20120301 |
| Perioperative rupture of the LIMA graft leading to cardiogenic shock, emergency angiography, and stenting with a polytetrafluoroethylene-covered stent. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120301 |
| Effects of everolimus in combination with sildenafil in monocrotaline-induced pulmonary hypertension in rats. | Cardiovascular toxicology 20120301 |
| New targeted therapies in pituitary carcinoma resistant to temozolomide. | Pituitary 20120301 |
| A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. | Cancer chemotherapy and pharmacology 20120301 |
| Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20120301 |
| Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. | Neuro-oncology 20120301 |
| Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. | Clinical genitourinary cancer 20120301 |
| Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. | The Journal of clinical endocrinology and metabolism 20120301 |
| Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? | Atherosclerosis 20120301 |
| The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats. | Transplant international : official journal of the European Society for Organ Transplantation 20120301 |
| Polycystic kidney disease: a 2011 update. | Current opinion in nephrology and hypertension 20120301 |
| mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. | Current treatment options in oncology 20120301 |
| Fatal acute pulmonary injury associated with everolimus. | The Annals of pharmacotherapy 20120301 |
| Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20120301 |
| Current status of immunosuppressive agents for solid organ transplantation in children. | Pediatric transplantation 20120301 |
| Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. | The oncologist 20120301 |
| Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors. | Transplantation 20120227 |
| Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. | Transplantation 20120227 |
| Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. | British journal of cancer 20120227 |
| Everolimus alters white matter diffusion in tuberous sclerosis complex. | Neurology 20120221 |
| New therapies for tuber-less sclerosis: white matter matters? | Neurology 20120221 |
| Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. | Biochemical pharmacology 20120215 |
| Breast Cancer: Blocking both driver and escape pathways improves outcomes. | Nature reviews. Clinical oncology 20120214 |
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. | The New England journal of medicine 20120209 |
| Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. | Investigational new drugs 20120201 |
| Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. | Pediatric blood & cancer 20120201 |
| [PI3K-AKT-mTOR pathway and cancer]. | Bulletin du cancer 20120201 |
| An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. | European journal of cancer (Oxford, England : 1990) 20120201 |
| [Intermittent fever under iatrogenic immunosuppression]. | Der Internist 20120201 |
| Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. | The British journal of dermatology 20120201 |
| mTOR as a therapeutic target in patients with gastric cancer. | International journal of cancer 20120201 |
| Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration. | Journal of cardiovascular pharmacology 20120201 |
| Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. | Journal of vascular surgery 20120201 |
| Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120201 |
| Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. | Molecular cancer therapeutics 20120201 |
| Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. | Endocrine-related cancer 20120201 |
| Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201 |
| Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. | Paediatric drugs 20120201 |
| Major response to everolimus in melanoma with acquired imatinib resistance. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201 |
| Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. | Journal of vascular surgery 20120201 |
| Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. | European journal of cancer (Oxford, England : 1990) 20120201 |
| Increasingly aggressive endovascular management of tibial artery occlusive disease. | Journal of vascular surgery 20120201 |
| Calcified in-stent restenosis: a rare cause of dilation failure requiring rotational atherectomy. | Circulation. Cardiovascular interventions 20120201 |
| Automated image analysis of nuclear shape: what can we learn from a prematurely aged cell? | Aging 20120201 |
| Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes. | JACC. Cardiovascular interventions 20120201 |
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies. | Journal of the National Cancer Institute 20120118 |
| Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. | NeuroImage 20120102 |
| mTOR pathway inhibition in renal cell carcinoma. | Urologic oncology 20120101 |
| An update on targeted therapy in metastatic renal cell carcinoma. | Urologic oncology 20120101 |
| Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. | The international journal of cardiovascular imaging 20120101 |
| Reproducibility of Shin's method for necrotic core and calcium content in atherosclerotic coronary lesions treated with bioresorbable everolimus-eluting vascular scaffolds using volumetric intravascular ultrasound radiofrequency-based analysis. | The international journal of cardiovascular imaging 20120101 |
| Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20120101 |
| Everolimus-eluting stents for treatment of chronic total coronary occlusions. | Clinical research in cardiology : official journal of the German Cardiac Society 20120101 |
| Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20120101 |
| Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. | Cancer chemotherapy and pharmacology 20120101 |
| A theoretical model to characterize the drug release behavior of drug-eluting stents with durable polymer matrix coating. | Journal of biomedical materials research. Part A 20120101 |
| Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. | European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 20120101 |
| Spatial distribution and temporal evolution of scattering centers by optical coherence tomography in the poly(L-lactide) backbone of a bioresorbable vascular scaffold. | Circulation journal : official journal of the Japanese Circulation Society 20120101 |
| Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis. | Circulation journal : official journal of the Japanese Circulation Society 20120101 |
| mTOR inhibitor-associated proteinuria in kidney transplant recipients. | Transplantation reviews (Orlando, Fla.) 20120101 |
| Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. | Molecular medicine (Cambridge, Mass.) 20120101 |
| Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20120101 |
| Intravascular ultrasound assessment of postprocedural incomplete stent apposition. | The Journal of invasive cardiology 20120101 |
| mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma. | Current medicinal chemistry 20120101 |
| Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA. | BMC clinical pharmacology 20120101 |
| Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation. | Journal of nephrology 20120101 |
| Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis. | Renal failure 20120101 |
| Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. | Cell death & disease 20120101 |
| Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. | Transplantation proceedings 20120101 |
| First-in-man study of simvastatin-eluting stent in de novo coronary lesions: the SIMVASTENT study. | Circulation journal : official journal of the Japanese Circulation Society 20120101 |
| Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? | European journal of dermatology : EJD 20120101 |
| Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news). | Harvard health letter 20120101 |
| Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. | PloS one 20120101 |
| [Metastatic breast cancer. Everolimus --a drug delays the progression of the tumor]. | Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec 20120101 |
| The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial. | Trials 20120101 |
| Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. | Annals of transplantation 20120101 |
| Targeting mTOR pathways in human malignancies. | Current pharmaceutical design 20120101 |
| Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments. | Circulation journal : official journal of the Japanese Circulation Society 20120101 |
| Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus eluting stent in a consecutive cohort of patients at a tertiary medical center. | Vascular health and risk management 20120101 |
| [Neuroendocrine tumors: the age of targeted therapies]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101 |
| Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. | Dermatology (Basel, Switzerland) 20120101 |
| Simultaneous determination of cyclosporine A, tacrolimus, sirolimus, and everolimus in whole-blood samples by LC-MS/MS. | TheScientificWorldJournal 20120101 |
| Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. | PloS one 20120101 |
| Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. | Biological & pharmaceutical bulletin 20120101 |
| BOLERO-2 - will this change practice in advanced breast cancer? | Breast cancer research : BCR 20120101 |
| Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries. | Cardiovascular diabetology 20120101 |
| Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. | PloS one 20120101 |
| Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. | Journal of toxicology and environmental health. Part A 20120101 |
| Occurrence of late acquired peri-stent contrast staining: comparison between sirolimus-eluting stents and everolimus-eluting stents. | International heart journal 20120101 |
| Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient. | International heart journal 20120101 |
| A case of pancreatic cancer after heart transplantation. | International heart journal 20120101 |
| Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. | Oncology 20120101 |
| Sunitinib and everolimus in pancreatic neuroendocrine tumors. | Tumori 20120101 |
| Mid-term clinical outcomes of ACS and non-ACS patients treated with everolimus-eluting stents. | International heart journal 20120101 |
| Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma. | Journal of biopharmaceutical statistics 20120101 |
| Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. | PloS one 20120101 |
| The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. | Cancer letters 20111226 |
| mTOR inhibitor therapy for patients with carcinoid. | Lancet (London, England) 20111210 |
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. | Lancet (London, England) 20111210 |
| Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. | Investigational new drugs 20111201 |
| Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. | Medical oncology (Northwood, London, England) 20111201 |
| Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. | Medical oncology (Northwood, London, England) 20111201 |
| 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. | International journal of cardiology 20111201 |
| Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20111201 |
| Evaluation of the MassTrak Immunosuppressant XE Kit for the determination of everolimus and cyclosporin A in human whole blood employing isotopically labeled internal standards. | Clinical chemistry and laboratory medicine 20111201 |
| Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. | Cancer letters 20111201 |
| m-TOR inhibitors: what role in liver transplantation? | Journal of hepatology 20111201 |
| Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20111201 |
| Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. | European urology 20111201 |
| Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. | Pediatric transplantation 20111201 |
| Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111201 |
| Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials. | Journal of interventional cardiology 20111201 |
| Pregnancy under everolimus-based immunosuppression. | Transplant international : official journal of the European Society for Organ Transplantation 20111201 |
| Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. | Transplant international : official journal of the European Society for Organ Transplantation 20111201 |
| Late withdrawal of calcineurin inhibitors and switch to mTOR inhibitors--beneficial or too late? | Pediatric transplantation 20111201 |
| Integration of diffusion-weighted MRI data and a simple mathematical model to predict breast tumor cellularity during neoadjuvant chemotherapy. | Magnetic resonance in medicine 20111201 |
| Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. | The Journal of clinical endocrinology and metabolism 20111201 |
| Autophagy in atherosclerosis: a potential drug target for plaque stabilization. | Arteriosclerosis, thrombosis, and vascular biology 20111201 |
| Bifurcation stenting with a provisional T strategy: drug eluting stent type does matter. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20111201 |
| Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20111201 |
| [Antihormonal therapy in breast cancer and mTOR inhibitors]. | Bulletin du cancer 20111201 |
| Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. | American heart journal 20111201 |
| Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. | Transplantation proceedings 20111201 |
| Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. | JACC. Cardiovascular interventions 20111201 |
| Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. | JACC. Cardiovascular interventions 20111201 |
| A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). | JACC. Cardiovascular interventions 20111201 |
| Everolimus prevents endomyocardial remodeling after heart transplantation. | Transplantation 20111127 |
| Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. | British journal of cancer 20111122 |
| Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. | Cancer 20111115 |
| Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. | Cancer research 20111115 |
| Differences in drug-eluting stents used in coronary artery disease. | The American journal of the medical sciences 20111101 |
| Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. | Human pathology 20111101 |
| Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20111101 |
| Monitoring of mycophenolic acid and kidney function during combined immunosuppressive therapy. | Clinical chemistry and laboratory medicine 20111101 |
| mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. | Laboratory investigation; a journal of technical methods and pathology 20111101 |
| Elimination of norovirus in a chronic carrier under immunosuppression after heart transplantation--effect of everolimus. | Transplant international : official journal of the European Society for Organ Transplantation 20111101 |
| Role of everolimus in pancreatic neuroendocrine tumors. | Expert review of anticancer therapy 20111101 |
| [Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of platinum-based chemotherapy (CRAD001)]. | Der Urologe. Ausg. A 20111101 |
| Successful treatment of a late presentation exercise-induced spontaneous left anterior descending artery dissection. | The Journal of invasive cardiology 20111101 |
| [Management of metastatic neuroendocrine tumors]. | Annales de pathologie 20111101 |
| Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administration. | Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 20111101 |
| De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients. | Transplantation proceedings 20111101 |
| Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. | JACC. Cardiovascular interventions 20111101 |
| Second-generation everolimus-eluting stents and the beat goes on? | JACC. Cardiovascular interventions 20111101 |
| Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20111030 |
| Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. | Journal of the American College of Cardiology 20111025 |
| Head-to-head randomized comparisons of limus-eluting coronary stents: pursuing excellence or flying too high? | Journal of the American College of Cardiology 20111025 |
| Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. | Journal of the American College of Cardiology 20111004 |
| Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. | Journal of the American College of Cardiology 20111004 |
| The magic of disappearing stents. | Journal of the American College of Cardiology 20111004 |
| North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. | International journal of radiation oncology, biology, physics 20111001 |
| Assessment of the serial changes of vessel wall contents in atherosclerotic coronary lesion with bioresorbable everolimus-eluting vascular scaffolds using Shin's method: an IVUS study. | The international journal of cardiovascular imaging 20111001 |
| Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. | European journal of cancer (Oxford, England : 1990) 20111001 |
| Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. | European heart journal 20111001 |
| Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. | Acta oncologica (Stockholm, Sweden) 20111001 |
| Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111001 |
| Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection. | Pediatric cardiology 20111001 |
| Everolimus tablets for patients with subependymal giant cell astrocytoma. | Expert opinion on pharmacotherapy 20111001 |
| Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. | Journal of neurochemistry 20111001 |
| Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. | Endocrine 20111001 |
| Clinical presentation and management of mTOR inhibitor-associated stomatitis. | Oral oncology 20111001 |
| New target therapies for patients with neuroendocrine tumors of the pancreas. | Expert review of gastroenterology & hepatology 20111001 |
| [The BASKET-PROVE study]. | Giornale italiano di cardiologia (2006) 20111001 |
| Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus. | Anticancer research 20111001 |
| Bioresorbable polymeric vascular scaffolds: a cautionary tale. | Circulation. Cardiovascular interventions 20111001 |
| Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. | JACC. Cardiovascular interventions 20111001 |
| Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. | JACC. Cardiovascular interventions 20111001 |
| Should everolimus-eluting stents be preferred in patients with acute and stable coronary syndromes? | JACC. Cardiovascular interventions 20111001 |
| Three-dimensional reconstruction of the post-dilated ABSORB everolimus-eluting bioresorbable vascular scaffold in a true bifurcation lesion for flow restoration. | JACC. Cardiovascular interventions 20111001 |
| Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. | Transplantation 20110927 |
| [RAD001 reverses radio-resistance and exerts synergistic tumor inhibition with 5-fluorouracil]. | Zhonghua yi xue za zhi 20110927 |
| Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. | Journal of the American College of Cardiology 20110920 |
| A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. | Cancer 20110915 |
| Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. | Cancer 20110915 |
| Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. | Transplantation 20110915 |
| Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901 |
| Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. | Heart (British Cardiac Society) 20110901 |
| Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110901 |
| Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. | Xenobiotica; the fate of foreign compounds in biological systems 20110901 |
| [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. | Der Urologe. Ausg. A 20110901 |
| New therapeutic options for metastatic malignant insulinomas. | Clinical endocrinology 20110901 |
| Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. | Acta dermato-venereologica 20110901 |
| Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. | International journal of oncology 20110901 |
| Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS. | Clinical genitourinary cancer 20110901 |
| The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. | Anticancer research 20110901 |
| Long-term experience with everolimus in kidney transplantation in the United States. | Transplantation proceedings 20110901 |
| A retrospective 12-month study of conversion to everolimus in lung transplant recipients. | Transplantation proceedings 20110901 |
| Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. | Future oncology (London, England) 20110901 |
| Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. | JACC. Cardiovascular interventions 20110901 |
| Total aorto-ostial chronic occlusion of the right coronary artery successfully recanalized via retrograde approach. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110901 |
| [Everolimus-eluting stent]. | Nihon rinsho. Japanese journal of clinical medicine 20110901 |
| [Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells]. | Zhonghua yi xue za zhi 20110830 |
| Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. | Transplantation 20110827 |
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Blood 20110825 |
| Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. | Circulation 20110823 |
| Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. | Circulation 20110823 |
| Is diabetes the achilles' heel of limus-eluting stents? | Circulation 20110823 |
| Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas. | International journal of cancer 20110815 |
| Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. | The American journal of cardiology 20110815 |
| Everolimus and long-term outcomes in renal transplantation: seeking an optimal strategy for immunosuppression. | Transplantation 20110815 |
| Everolimus and long-term outcomes in renal transplantation. | Transplantation 20110815 |
| Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810 |
| The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. | Breast cancer research and treatment 20110801 |
| Are we missing the mTOR target in breast cancer? | Breast cancer research and treatment 20110801 |
| Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. | Journal of hepatology 20110801 |
| The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 20110801 |
| Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20110801 |
| Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110801 |
| Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials. | Journal of interventional cardiology 20110801 |
| Focus. | Journal of hepatology 20110801 |
| Cholesterol esters as growth regulators of lymphocytic leukaemia cells. | Cell proliferation 20110801 |
| First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. | Journal of vascular surgery 20110801 |
| The use of everolimus in pediatric liver transplant recipients: first experience in a single center. | Pediatric transplantation 20110801 |
| Evaluation of performance of new, isotopically labeled internal standard ([13c2d4]RAD001) for everolimus using a novel high-performance liquid chromatography tandem mass spectrometry method. | Therapeutic drug monitoring 20110801 |
| mTOR inhibitors in advanced renal cell carcinoma. | Hematology/oncology clinics of North America 20110801 |
| How can we miss you, if you will never leave? Biodegradable stents. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110801 |
| Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. | Circulation. Cardiovascular interventions 20110801 |
| A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. | The oncologist 20110801 |
| Everolimus vs. rapamycin for treating diabetic nephropathy in diabetic mouse model. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20110801 |
| Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. | Expert review of anticancer therapy 20110801 |
| A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. | Cancer discovery 20110801 |
| Everolimus for cardiac allograft vasculopathy--every patient, at any time? | Transplantation 20110727 |
| Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. | Transplantation 20110727 |
| [Adverse effects of new oncologic therapies]. | Praxis 20110727 |
| PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. | Oncogene 20110721 |
| 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. | Journal of the American College of Cardiology 20110712 |
| Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. | The international journal of cardiovascular imaging 20110701 |
| Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. | International journal of cardiology 20110701 |
| Percutaneous intervention of a thrombotic-occluded saphenous vein graft successfully treated using the undersized stent approach to prevent distal embolization. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110701 |
| An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. | Respirology (Carlton, Vic.) 20110701 |
| Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110701 |
| Primum non nocere: safety in clinical trials for IPF. | Respirology (Carlton, Vic.) 20110701 |
| Meta-analysis of everolimus-eluting stent as compared to sirolimus-eluting stent in patients undergoing percutaneous coronary interventions: an update. | International journal of cardiology 20110701 |
| Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. | Cancer chemotherapy and pharmacology 20110701 |
| Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma. | Journal of pediatric hematology/oncology 20110701 |
| High-throughput LC-MS/MS method for monitoring sirolimus and everolimus in the routine clinical laboratory. | Clinical chemistry and laboratory medicine 20110701 |
| An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. | Expert opinion on pharmacotherapy 20110701 |
| The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110701 |
| Testing the strength of biodegradable stents. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110701 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20110701 |
| Successful stent implantation guided by intravascular ultrasound and a Doppler guidewire without contrast injection in a patient with allergy to iodinated contrast media. | The Journal of invasive cardiology 20110701 |
| Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110701 |
| 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). | Journal of the American College of Cardiology 20110628 |
| Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. | Journal of the American College of Cardiology 20110628 |
| Second-generation drug-eluting stents. Moving the field forward. | Journal of the American College of Cardiology 20110628 |
| A proof of concept phase II non-inferiority criterion. | Statistics in medicine 20110615 |
| Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents. | The American journal of cardiology 20110615 |
| Comparison of everolimus-eluting stent with paclitaxel-eluting stent in long chronic total occlusions. | The American journal of cardiology 20110615 |
| Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. | International urology and nephrology 20110601 |
| Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110601 |
| Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110601 |
| Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. | Japanese journal of clinical oncology 20110601 |
| mTOR inhibition, a potential novel approach for bronchial carcinoids. | Endocrine-related cancer 20110601 |
| The real world experience of the everolimus-eluting coronary stent system: audit of everolimus-eluting coronary stents. | Journal of interventional cardiology 20110601 |
| Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. | Clinical & experimental metastasis 20110601 |
| Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. | Targeted oncology 20110601 |
| Treatment of metastatic renal cell carcinoma and renal pelvic cancer. | Clinical and experimental nephrology 20110601 |
| Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. | European journal of cancer (Oxford, England : 1990) 20110601 |
| Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. | The oncologist 20110601 |
| Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. | Molecular cancer therapeutics 20110601 |
| Common toxicities of mammalian target of rapamycin inhibitors. | Targeted oncology 20110601 |
| Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study. | Transplantation proceedings 20110601 |
| Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster. | Transplantation proceedings 20110601 |
| Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. | Transplantation proceedings 20110601 |
| The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). | Journal of the American College of Cardiology 20110531 |
| Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years. | Transplantation 20110527 |
| Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study. | Transplantation 20110527 |
| Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. | Journal of the American College of Cardiology 20110524 |
| Advances in pancreatic neuroendocrine tumor treatment. | The New England journal of medicine 20110512 |
| Everolimus- and temsirolimus-associated enteritis: report of three cases. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110510 |
| Everolimus interferes with the inflammatory phase of healing in experimental colonic anastomoses. | The Journal of surgical research 20110501 |
| Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110501 |
| Somatostatin analogues for treatment of polycystic liver disease. | Current opinion in gastroenterology 20110501 |
| Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20110501 |
| Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. | European journal of cancer (Oxford, England : 1990) 20110501 |
| Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110501 |
| Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. | The oncologist 20110501 |
| Regression of a cardiac rhabdomyoma in a patient receiving everolimus. | Pediatrics 20110501 |
| Everolimus for the treatment of advanced renal cell carcinoma. | Expert opinion on pharmacotherapy 20110501 |
| Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110501 |
| PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110501 |
| Impact of drug-eluting stent type on periprocedural myocardial necrosis. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110501 |
| Usefulness of rotational atherectomy in preventing polymer damage of everolimus-eluting stent in calcified coronary artery. | JACC. Cardiovascular interventions 20110501 |
| Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study. | Transplantation proceedings 20110501 |
| Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110501 |
| A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110501 |
| [Novelties in the treatment for advanced renal-cell cancer]. | Orvosi hetilap 20110424 |
| Recent studies show promise for treating rare pancreatic tumors. | Journal of the National Cancer Institute 20110420 |
| A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. | Journal of the American College of Cardiology 20110419 |
| Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. | Lancet (London, England) 20110409 |
| Long-term safety and efficacy of drug-eluting stents. | Lancet (London, England) 20110409 |
| A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. | Investigational new drugs 20110401 |
| Melanoma: from darkness to promise. | American journal of clinical oncology 20110401 |
| Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. | European urology 20110401 |
| Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: comparison with liquid chromatography/mass spectrometry. | Therapeutic drug monitoring 20110401 |
| The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. | Endocrine-related cancer 20110401 |
| The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. | JACC. Cardiovascular interventions 20110401 |
| Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110401 |
| mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. | Neurosurgery 20110401 |
| Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320 |
| Translational medicine: Cancer lessons from mice to humans. | Nature 20110317 |
| Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). | The American journal of cardiology 20110315 |
| Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). | The American journal of cardiology 20110315 |
| Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011. | JOP : Journal of the pancreas 20110309 |
| Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. | Lancet (London, England) 20110305 |
| Immunosuppression without calcineurin inhibition: by ZEUS. | Lancet (London, England) 20110305 |
| Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110301 |
| Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models. | Annals of hematology 20110301 |
| Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. | Experimental dermatology 20110301 |
| Primary percutaneous coronary intervention of an unprotected left main using mini-crush drug-eluting stents facilitated by intracoronary reteplase. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110301 |
| Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus. | Oncology nursing forum 20110301 |
| CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. | Transplantation 20110301 |
| Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. | Aging 20110301 |
| Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. | JACC. Cardiovascular interventions 20110301 |
| Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. | Targeted oncology 20110301 |
| Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. | Life sciences 20110227 |
| mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110220 |
| Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110215 |
| Everolimus for advanced pancreatic neuroendocrine tumors. | The New England journal of medicine 20110210 |
| Promising advances in the treatment of malignant pancreatic endocrine tumors. | The New England journal of medicine 20110210 |
| Everolimus and giant-cell astrocytomas in tuberous sclerosis. | The New England journal of medicine 20110210 |
| Everolimus and giant-cell astrocytomas in tuberous sclerosis. | The New England journal of medicine 20110210 |
| Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20110201 |
| Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods. | Clinical biochemistry 20110201 |
| A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). | Cancer chemotherapy and pharmacology 20110201 |
| mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. | Journal of hepatology 20110201 |
| Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. | Cancer letters 20110201 |
| A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. | European heart journal 20110201 |
| A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. | Leukemia 20110201 |
| Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. | Annals of medicine 20110201 |
| Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. | Transplant international : official journal of the European Society for Organ Transplantation 20110201 |
| Infected coronary artery pseudoaneurysm after repeated percutaneous coronary intervention. | The Annals of thoracic surgery 20110201 |
| Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect? | Annals of oncology : official journal of the European Society for Medical Oncology 20110201 |
| Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. | Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20110201 |
| Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. | The oncologist 20110201 |
| Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. | The oncologist 20110201 |
| Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. | The oncologist 20110201 |
| The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. | JACC. Cardiovascular interventions 20110201 |
| [Types and characteristic features of drug-eluting stents]. | Nihon rinsho. Japanese journal of clinical medicine 20110201 |
| Ten-month laryngeal allograft survival with use of pulsed everolimus and anti-alphabeta T-cell receptor antibody immunosuppression. | The Annals of otology, rhinology, and laryngology 20110201 |
| mTOR inhibitors and autosomal dominant polycystic kidney disease. | The New England journal of medicine 20110120 |
| mTOR inhibitors and autosomal dominant polycystic kidney disease. | The New England journal of medicine 20110120 |
| mTOR inhibitors and autosomal dominant polycystic kidney disease. | The New England journal of medicine 20110120 |
| Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients. | Transplantation 20110115 |
| The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. | Clinical transplantation 20110101 |
| Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model. | Cancer chemotherapy and pharmacology 20110101 |
| Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? | Transplant international : official journal of the European Society for Organ Transplantation 20110101 |
| Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 20110101 |
| Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. | Anti-cancer drugs 20110101 |
| The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. | Haematologica 20110101 |
| Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. | Japanese journal of clinical oncology 20110101 |
| Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. | Neurotoxicology 20110101 |
| Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. | Breast cancer research and treatment 20110101 |
| The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. | Atherosclerosis 20110101 |
| Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. | Clinical transplantation 20110101 |
| Control of carcinoid syndrome with everolimus. | Annals of oncology : official journal of the European Society for Medical Oncology 20110101 |
| Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib. | Nephrology (Carlton, Vic.) 20110101 |
| Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. | The Annals of pharmacotherapy 20110101 |
| Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. | Journal of hematology & oncology 20110101 |
| Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. | Journal of nephrology 20110101 |
| Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Clinical evidence on the use of anti-mTOR drugs in renal transplantation. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101 |
| Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. | Molecular cancer 20110101 |
| Retrospective analyses of patient characteristics having predictive impact on survival under everolimus. | Onkologie 20110101 |
| Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. | Breast cancer research : BCR 20110101 |
| [Immunosuppressive agents in kidney transplantation]. | Nihon Jinzo Gakkai shi 20110101 |
| [Autosomal dominant polycystic kidney disease]. | Nihon Jinzo Gakkai shi 20110101 |
| Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen. | Clinical transplantation 20110101 |
| The impact of new generation drug-eluting stent implantation on patients with chronic kidney disease and a single lesion in the proximal segment of the left anterior descending artery. | Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20110101 |
| Rapid estimation of whole blood everolimus concentrations using architect sirolimus immunoassay and mathematical equations: comparison with everolimus values determined by liquid chromatography/mass spectrometry. | Journal of clinical laboratory analysis 20110101 |
| [Breast cancer therapy with combination of endocrine and target drugs]. | Voprosy onkologii 20110101 |
| Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. | Oncology 20110101 |
| The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. | PloS one 20110101 |
| Determination of blood everolimus concentrations in kidney and liver transplant recipients using the sirolimus antibody conjugated magnetic immunoassay (ACMIA). | Clinical laboratory 20110101 |
| Everolimus in clinical practice in long-term liver transplantation: an observational study. | Transplantation proceedings 20110101 |
| Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. | Transplantation proceedings 20110101 |
| Conversion to everolimus in liver transplant patients with renal dysfunction. | Transplantation proceedings 20110101 |
| Long-term use of everolimus in lung transplant patients. | Transplantation proceedings 20110101 |
| Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. | BMC cancer 20110101 |
| c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. | Molecular cancer 20110101 |
| Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101 |
| The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. | BMC cancer 20110101 |
| Neoadjuvant chemotherapy and targeted therapies: a promising strategy. | Journal of the National Cancer Institute. Monographs 20110101 |
| [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101 |
| Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. | PloS one 20110101 |
| Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. | Trials 20110101 |
| S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. | PloS one 20110101 |
| Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. | BMC cancer 20110101 |
| Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. | Internal medicine (Tokyo, Japan) 20110101 |
| Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient. | Annals of transplantation 20110101 |
| Procedure for determination of immunosuppressive drugs in whole blood with liquid chromatography-isotope dilution mass spectrometry. | Clinical laboratory 20110101 |
| Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. | Oncology research 20110101 |
| Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. | Transplantation 20101227 |
| RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. | Cancer letters 20101218 |
| Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. | Cancer research 20101215 |
| Mammalian target of rapamycin: biological function and target for novel anticancer agents. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20101215 |
| Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). | Journal of the American College of Cardiology 20101214 |
| Drug-eluting versus bare-metal stents in large coronary arteries. | The New England journal of medicine 20101209 |
| Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. | Cancer letters 20101208 |
| Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus. | Investigational new drugs 20101201 |
| TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. | Investigational new drugs 20101201 |
| A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. | Cancer 20101201 |
| Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101201 |
| Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. | European urology 20101201 |
| Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101201 |
| Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance. | Scandinavian journal of clinical and laboratory investigation 20101201 |
| Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101201 |
| The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20101201 |
| Do mTOR inhibitors still have a future in ADPKD? | Nature reviews. Nephrology 20101201 |
| Recurrent stent fracture: first reported image of everolimus-eluting stent fracture leading to recurrent restenosis in cardiac allograft vasculopathy. | The Journal of invasive cardiology 20101201 |
| Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. | Transplantation proceedings 20101201 |
| More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. | Anticancer research 20101201 |
| Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. | JACC. Cardiovascular interventions 20101201 |
| Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomize | JACC. Cardiovascular interventions 20101201 |
| Dedicated everolimus-eluting side branch access system: XIENCE SBA. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20101201 |
| Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20101201 |
| Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. | Circulation 20101130 |
| Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. | Circulation 20101130 |
| Bevacizumab and everolimus in renal cancer: a rational way forward. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120 |
| Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. | The New England journal of medicine 20101104 |
| Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. | Transplant international : official journal of the European Society for Organ Transplantation 20101101 |
| Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20101101 |
| Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20101101 |
| Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. | Kidney international 20101101 |
| Lipids and renal cystic disease. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101 |
| Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. | Current oncology reports 20101101 |
| Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. | International journal of hematology 20101101 |
| Warning: this report does not address heavily calcified coronary arteries. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20101101 |
| More openness and a little less strut: two good ideas for stents and the people who implant them. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20101101 |
| Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20101101 |
| A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. | JACC. Cardiovascular interventions 20101101 |
| In vivo assessment of local intravascular hemodynamics and arterial morphology to investigate vascular outcomes: a growing field coming of age. | JACC. Cardiovascular interventions 20101101 |
| Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. | Transplantation proceedings 20101101 |
| Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. | Transplantation proceedings 20101101 |
| Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients. | Transplantation proceedings 20101101 |
| Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. | Transplantation proceedings 20101101 |
| Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. | Transplantation proceedings 20101101 |
| The therapy of kidney cancer with biomolecular drugs. | Cancer treatment reviews 20101101 |
| Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. | Cancer treatment reviews 20101101 |
| mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. | Cancer letters 20101028 |
| Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20101001 |
| A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20101001 |
| De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20101001 |
| 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20101001 |
| Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001 |
| Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. | Pharmacotherapy 20101001 |
| Does early (CNI) conversion lead to eternal (renal) salvation? | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20101001 |
| Current status of the Xience V® everolimus-eluting coronary stent system. | Expert review of cardiovascular therapy 20101001 |
| Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years. | Transplantation proceedings 20101001 |
| Proliferation signal inhibitors in heart transplantation: a 5-year experience. | Transplantation proceedings 20101001 |
| Temporal trends in the use of proliferation signal inhibitors in maintenance heart transplantation: a Spanish multicenter study. | Transplantation proceedings 20101001 |
| Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. | Transplantation proceedings 20101001 |
| Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. | Transplantation proceedings 20101001 |
| Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. | Health technology assessment (Winchester, England) 20101001 |
| Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. | British journal of cancer 20100928 |
| [Everolimus-associated pneumonitis in adult liver transplant recipient]. | Medicina clinica 20100918 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. | Cancer 20100915 |
| Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. | Medical oncology (Northwood, London, England) 20100901 |
| Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. | Annals of oncology : official journal of the European Society for Medical Oncology 20100901 |
| Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. | Transplant international : official journal of the European Society for Organ Transplantation 20100901 |
| Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. | Annals of surgical oncology 20100901 |
| Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. | Cancer letters 20100901 |
| Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. | Endocrine-related cancer 20100901 |
| Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. | Cancer 20100901 |
| Everolimus: efficacy and safety in cardiac transplantation. | Expert opinion on drug safety 20100901 |
| Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. | Molecular cancer research : MCR 20100901 |
| [Second line AUO study AB35/09 of metastasized urothelial cell carcinoma]. | Der Urologe. Ausg. A 20100901 |
| Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials. | Expert review of cardiovascular therapy 20100901 |
| Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent. | Expert review of cardiovascular therapy 20100901 |
| Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation. | Transplantation proceedings 20100901 |
| American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. | Expert review of anticancer therapy 20100901 |
| Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100901 |
| Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100901 |
| Vascular response to a third generation everolimus-eluting stent. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100901 |
| Murine cytomegalovirus infection leads to increased levels of transplant arteriosclerosis in a murine aortic allograft model. | Transplantation 20100827 |
| Everolimus in patients with autosomal dominant polycystic kidney disease. | The New England journal of medicine 20100826 |
| mTOR inhibitors in polycystic kidney disease. | The New England journal of medicine 20100826 |
| Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. | British journal of cancer 20100824 |
| Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. | Cancer 20100815 |
| Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer. | Cancer research 20100815 |
| Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. | The American journal of cardiology 20100815 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. | The Journal of clinical investigation 20100802 |
| PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. | The Journal of clinical investigation 20100802 |
| The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. | Investigational new drugs 20100801 |
| Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients. | Transplant international : official journal of the European Society for Organ Transplantation 20100801 |
| Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. | American journal of respiratory and critical care medicine 20100801 |
| Surface characterization of poly(lactic acid)/everolimus and poly(ethylene vinyl alcohol)/everolimus stents. | Drug delivery 20100801 |
| Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. | Experimental hematology 20100801 |
| Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. | Arthritis and rheumatism 20100801 |
| Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. | Therapeutic drug monitoring 20100801 |
| The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? | BJU international 20100801 |
| In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction. | Transplant immunology 20100801 |
| The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. | Molecular cancer research : MCR 20100801 |
| 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. | JACC. Cardiovascular interventions 20100801 |
| Everolimus in renal cell carcinoma. | Drugs of today (Barcelona, Spain : 1998) 20100801 |
| Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network database. | Transplantation 20100715 |
| Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. | Transplantation 20100715 |
| Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. | The New England journal of medicine 20100708 |
| Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. | Apoptosis : an international journal on programmed cell death 20100701 |
| Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. | Carcinogenesis 20100701 |
| New developments in targeted therapy for soft tissue sarcoma. | Current oncology reports 20100701 |
| Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. | Transplant immunology 20100701 |
| New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? | Current opinion in oncology 20100701 |
| Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. | Breast cancer research and treatment 20100701 |
| Which DES for diabetics? Round 1: A draw. Round 2: Everolimus leading? | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100701 |
| An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100701 |
| Another small step for small vessels. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100701 |
| SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. | The American journal of cardiology 20100701 |
| Clinical recommendations for the use of everolimus in heart transplantation. | Transplantation reviews (Orlando, Fla.) 20100701 |
| [Current impact of natural products in the discovery of anticancer drugs]. | Annales pharmaceutiques francaises 20100701 |
| Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients. | Transplant international : official journal of the European Society for Organ Transplantation 20100601 |
| Proximal protection in recanalization of totally occluded saphenous vein grafts in acute coronary syndrome. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100601 |
| Update on systemic therapies of metastatic renal cell carcinoma. | World journal of urology 20100601 |
| Reversible severe synovitis associated with everolimus. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20100601 |
| Substitution of corticosteroid with everolimus after lung transplantation: a pediatric case report. | Pharmacy world & science : PWS 20100601 |
| Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20100601 |
| Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. | Anti-cancer drugs 20100601 |
| Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. | Cancer biology & therapy 20100601 |
| Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100601 |
| Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. | Cancer research 20100601 |
| Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100601 |
| Long-term follow-up of the First In Man experience with everolimus-eluting stents. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100601 |
| Procedure-related myonecrosis after bare and drug-eluting stent implantation. | Asian cardiovascular & thoracic annals 20100601 |
| [mTOR inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay. | Transplantation proceedings 20100601 |
| Initial experience with an everolimus-eluting, second-generation drug-eluting stent for treatment of intracranial atherosclerosis. | Journal of neurointerventional surgery 20100601 |
| Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. | The New England journal of medicine 20100506 |
| Second-generation drug-eluting coronary stents. | The New England journal of medicine 20100506 |
| Everolimus and pazopanib: two new drugs for renal cell cancer. | The Medical letter on drugs and therapeutics 20100503 |
| mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. | Leukemia research 20100501 |
| Sirolimus and everolimus clearance in maintenance kidney and liver transplant recipients: diagnostic efficiency of the concentration/dose ratio for the prediction of trough steady-state concentrations. | Upsala journal of medical sciences 20100501 |
| Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. | Transplant international : official journal of the European Society for Organ Transplantation 20100501 |
| Identification of functional FKB protein in Echinococcus granulosus: its involvement in the protoscolicidal action of rapamycin derivates and in calcium homeostasis. | International journal for parasitology 20100501 |
| IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100501 |
| Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. | European heart journal 20100501 |
| Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. | European journal of endocrinology 20100501 |
| The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. | Cancer 20100501 |
| A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. | American journal of hematology 20100501 |
| Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. | Journal of hepatology 20100501 |
| How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501 |
| Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501 |
| Novel immunosuppressive agents in kidney transplantation. | Clinical nephrology 20100501 |
| Vascular response to overlapping everolimus-eluting stents. - Comparison with paclitaxel-eluting stents -. | Circulation journal : official journal of the Japanese Circulation Society 20100501 |
| Everolimus in relapsed Hodgkin's lymphoma: something exciting or a case of caveat mTOR? | American journal of hematology 20100501 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20100501 |
| [Gingival hyperplasia secondary to everolimus therapy]. | Actas dermo-sifiliograficas 20100501 |
| De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis. | Transplantation proceedings 20100501 |
| Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale. | Transplantation proceedings 20100501 |
| Once daily everolimus is safe and effective in de novo renal transplant recipients: six-month results of a pilot study. | Transplantation proceedings 20100501 |
| Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen. | Transplantation proceedings 20100501 |
| Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk? | Transplantation proceedings 20100501 |
| A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100501 |
| Present state of target therapy for disseminated renal cell carcinoma. | Immunotherapy 20100501 |
| Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. | Transplantation 20100427 |
| Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. | Transplantation 20100415 |
| Sensitive quantification of sirolimus and everolimus by LC-MS/MS with online sample cleanup. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100415 |
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410 |
| Everolimus-eluting versus paclitaxel-eluting stents. | Lancet (London, England) 20100403 |
| Everolimus-eluting versus paclitaxel-eluting stents. | Lancet (London, England) 20100403 |
| Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. | American journal of physiology. Renal physiology 20100401 |
| A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial. | Journal of cardiovascular medicine (Hagerstown, Md.) 20100401 |
| RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. | Oncology reports 20100401 |
| Palliative chemotherapy for pancreatic malignancies. | The Surgical clinics of North America 20100401 |
| Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. | JACC. Cardiovascular interventions 20100401 |
| Can cyclosporine blood level be reduced to half after heart transplantation? | Transplantation proceedings 20100401 |
| The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate. | Transplantation proceedings 20100401 |
| [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma]. | Revue medicale de Liege 20100401 |
| In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100401 |
| Lesion complexity determines arterial drug distribution after local drug delivery. | Journal of controlled release : official journal of the Controlled Release Society 20100319 |
| Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. | Chemical research in toxicology 20100315 |
| Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310 |
| Neuroendocrine tumors of the pancreas: what's new. Highlights from the '2010 ASCO Gastrointestinal Cancers Symposium'. Orlando, FL, USA. January 22-24, 2010. | JOP : Journal of the pancreas 20100305 |
| Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. | Cancer chemotherapy and pharmacology 20100301 |
| Everolimus. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100301 |
| [Recent progress in the molecular-targeting treatment of neuroendocrine tumors]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20100301 |
| Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. | The oncologist 20100301 |
| Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. | Transplantation proceedings 20100301 |
| [Vessel response evaluation by optical coherence tomography after drug-eluting stent implantation in the left main coronary artery]. | Giornale italiano di cardiologia (2006) 20100301 |
| StatBite: FDA oncology drug product approvals in 2009. | Journal of the National Cancer Institute 20100224 |
| Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. | Cancer research 20100215 |
| The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. | Molecular and cellular endocrinology 20100205 |
| Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach. | The European journal of health economics : HEPAC : health economics in prevention and care 20100201 |
| Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. | Transplant infectious disease : an official journal of the Transplantation Society 20100201 |
| Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100201 |
| Potential role of everolimus in inducing cholestasis. | Annals of oncology : official journal of the European Society for Medical Oncology 20100201 |
| Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. | The Journal of clinical endocrinology and metabolism 20100201 |
| Ultra fast liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of cyclosporin A, tacrolimus, sirolimus, and everolimus in whole blood using deuterated internal standards for cyclosporin A and everolimus. | Therapeutic drug monitoring 20100201 |
| RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. | Journal of cellular biochemistry 20100201 |
| Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. | Leukemia & lymphoma 20100201 |
| Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. | Journal of interventional cardiology 20100201 |
| A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. | Molecular endocrinology (Baltimore, Md.) 20100201 |
| New Drugs2010, PART 1. | Nursing 20100201 |
| Surgical biology for the clinician: vascular effects of immunosuppression. | Canadian journal of surgery. Journal canadien de chirurgie 20100201 |
| Augmentation of autophagy by mTOR-inhibition in myocardial infarction: When size matters. | Autophagy 20100201 |
| Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. | Molecular cancer therapeutics 20100201 |
| Diffuse alveolar hemorrhage induced by everolimus. | Chest 20100201 |
| Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. | International journal of clinical pharmacology and therapeutics 20100201 |
| A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100201 |
| Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. | Transplantation 20100127 |
| Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. | Lancet (London, England) 20100116 |
| Everolimus or paclitaxel stents in real life: go COMPARE. | Lancet (London, England) 20100116 |
| Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options. | Transplant international : official journal of the European Society for Organ Transplantation 20100101 |
| Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. | European heart journal 20100101 |
| mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. | Biochemical pharmacology 20100101 |
| Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. | Japanese journal of clinical oncology 20100101 |
| Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100101 |
| Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. | Coronary artery disease 20100101 |
| Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. | Transplant international : official journal of the European Society for Organ Transplantation 20100101 |
| Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. | Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 20100101 |
| Progress in the management of advanced renal cell carcinoma (RCC). | Aktuelle Urologie 20100101 |
| Long-term laryngeal allograft survival using low-dose everolimus. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20100101 |
| Lingual angioedema associated with everolimus. | Acta oncologica (Stockholm, Sweden) 20100101 |
| [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]. | Onkologie 20100101 |
| [Outlook: Future therapy of renal cell carcinoma]. | Onkologie 20100101 |
| Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. | Transplantation proceedings 20100101 |
| Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. | Transplantation proceedings 20100101 |
| South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens. | Transplantation proceedings 20100101 |
| Everolimus in lung transplantation in Chile. | Transplantation proceedings 20100101 |
| New therapeutic strategies for renal cell carcinoma. | Urologic nursing 20100101 |
| [Toxic effect of immunosuppression agent Everolimus on insuloma cells and pancreatic islets of SD rat]. | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100101 |
| A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. | BMC surgery 20100101 |
| [Renal cell carcinoma management and therapies in 2010]. | Bulletin du cancer 20100101 |
| [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]. | Bulletin du cancer 20100101 |
| [Advanced renal carcinomas with special situations. How to treat them?]. | Bulletin du cancer 20100101 |
| Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. | American journal of nephrology 20100101 |
| Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease. | Cardiology 20100101 |
| Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. | BMC cancer 20100101 |
| [Interstitial pneumonitis from everolimus]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101 |
| Severe stomatitis complicating immune-suppressive switch after cardiac transplantation. | Acta chirurgica Belgica 20100101 |
| Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review. | Transplantation proceedings 20100101 |
| Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. | Trials 20100101 |
| Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. | BMC cancer 20100101 |
| Targeted therapy in lymphoma. | Journal of hematology & oncology 20100101 |
| Primary PCI for acute anterior wall MI with pulmonary edema and left anterior descending artery ostial stenosis. | Indian heart journal 20100101 |
| Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. | Journal of experimental & clinical cancer research : CR 20100101 |
| Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug-eluting stent systems. | Current pharmaceutical design 20100101 |
| Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? | Tumori 20100101 |
| Perspectives in the development of novel treatment approaches. | Tumori 20100101 |
| Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. | Journal of the American College of Cardiology 20091215 |
| Assimilating the current clinical data of fully bioabsorbable stents. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20091215 |
| Everolimus-eluting bioabsorbable stent--Abbot Vascular programme. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20091215 |
| Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. | Cancer treatment reviews 20091201 |
| The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only. | Journal of interventional cardiology 20091201 |
| Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. | Leukemia & lymphoma 20091201 |
| Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. | American journal of physiology. Renal physiology 20091201 |
| Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. | Biopharmaceutics & drug disposition 20091201 |
| Emerging treatment combinations: integrating therapy into clinical practice. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201 |
| Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20091201 |
| Metastatic renal cell carcinoma: current standards of care. | Clinical journal of oncology nursing 20091201 |
| Management of mTOR inhibitor side effects. | Clinical journal of oncology nursing 20091201 |
| The role of mTOR in bladder cancer. | Cancer biology & therapy 20091201 |
| Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. | American heart journal 20091201 |
| Preprocedural inflammation does not affect neointimal hyperplasia following everolimus-eluting stent implantation. | The Journal of invasive cardiology 20091201 |
| Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. | Transplantation proceedings 20091201 |
| Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. | Transplantation proceedings 20091201 |
| Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. | Cancer biology & therapy 20091201 |
| [Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation]. | Nephrologie & therapeutique 20091201 |
| [Proliferation signal inhibitors: what therapeutic protocols are followed in 2009?]. | Nephrologie & therapeutique 20091201 |
| [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages]. | Nephrologie & therapeutique 20091201 |
| 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). | JACC. Cardiovascular interventions 20091201 |
| Clinical outcomes after unrestricted implantation of everolimus-eluting stents. | JACC. Cardiovascular interventions 20091201 |
| Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. | Transplantation 20091127 |
| The role of mTORC1 pathway in intestinal tumorigenesis. | Cell cycle (Georgetown, Tex.) 20091115 |
| Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20091101 |
| Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20091101 |
| Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. | Biochemical pharmacology 20091101 |
| Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. | Journal of dermatological science 20091101 |
| Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091101 |
| Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20091101 |
| Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20091101 |
| Transplantation: time to rethink immunosuppression by mTOR inhibitors? | Nature reviews. Nephrology 20091101 |
| Sirolimus: a novel immunosuppressive drug in heart transplantation. | Recent patents on cardiovascular drug discovery 20091101 |
| [Indications of mTOR inhibitors in liver transplantation]. | Gastroenterologie clinique et biologique 20091101 |
| Everolimus de novo in liver transplantation. | Gastroenterologie clinique et biologique 20091101 |
| [Antitumoral effect of proliferation signal inhibitors]. | Gastroenterologie clinique et biologique 20091101 |
| How should I treat a complex Post-CABG patient? | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20091101 |
| Everolimus: in advanced renal cell carcinoma. | Drugs 20091022 |
| Gastric cancer: trastuzumab trial results spur search for other targets. | Journal of the National Cancer Institute 20091007 |
| Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. | Cellular signalling 20091001 |
| Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. | International journal of cancer 20091001 |
| Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091001 |
| Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. | Annals of oncology : official journal of the European Society for Medical Oncology 20091001 |
| Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. | European heart journal 20091001 |
| SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. | American heart journal 20091001 |
| Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20091001 |
| Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920 |
| Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090901 |
| Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. | Biochemical pharmacology 20090901 |
| Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. | Endocrine-related cancer 20090901 |
| mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090901 |
| Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option. | Annals of the New York Academy of Sciences 20090901 |
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. | Blood 20090820 |
| Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. | Cancer 20090815 |
| Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. | Transplantation 20090815 |
| Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. | Transplantation 20090815 |
| Everolimus, a promising medical therapy for coronary heart disease? | Medical hypotheses 20090801 |
| Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. | Hepatology (Baltimore, Md.) 20090801 |
| Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. | Circulation. Cardiovascular interventions 20090801 |
| Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. | Transplantation 20090727 |
| Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. | Transplantation 20090715 |
| Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. | Transplantation 20090715 |
| The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. | Journal of the American College of Cardiology 20090714 |
| RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. | Journal of cellular and molecular medicine 20090701 |
| RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. | Autophagy 20090701 |
| The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients. | European journal of clinical pharmacology 20090701 |
| Everolimus. | Nature reviews. Drug discovery 20090701 |
| New mTOR inhibitor for renal cell cancer. | Oncology (Williston Park, N.Y.) 20090701 |
| A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: Insight to the drug release mechanisms. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090628 |
| Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. | Journal of the American College of Cardiology 20090616 |
| FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. | British journal of cancer 20090602 |
| Combination of immunosuppressive drugs leaves specific 'fingerprint' on gene expression in vitro. | Immunopharmacology and immunotoxicology 20090601 |
| A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. | Cancer 20090601 |
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601 |
| Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. | Expert review of anticancer therapy 20090601 |
| Bioabsorbable coronary stents. | Circulation. Cardiovascular interventions 20090601 |
| Targeting mTOR in renal cell carcinoma. | Cancer 20090515 |
| Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. | Biochemical pharmacology 20090515 |
| Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy. | Transplant international : official journal of the European Society for Organ Transplantation 20090501 |
| [Targeted therapies and their indications in solid neoplasias]. | La Revue de medecine interne 20090501 |
| Progress in the treatment of neuroendocrine tumors. | Current oncology reports 20090501 |
| Targeted therapies in metastatic renal cancer in 2009. | BJU international 20090501 |
| Ultra-performance hydrophilic interaction liquid chromatography/tandem mass spectrometry for the determination of everolimus in mouse plasma. | Rapid communications in mass spectrometry : RCM 20090501 |
| Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. | American heart journal 20090501 |
| New oral treatment for kidney cancer approved. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090501 |
| Intravascular ultrasound guidance of multiple drug-eluting stent implantation in lesions associated with coronary aneurysms. | The Journal of invasive cardiology 20090501 |
| Xience V everolimus-eluting coronary stent. | Expert review of medical devices 20090501 |
| The applicability of mTOR inhibition in solid tumors. | Current cancer drug targets 20090501 |
| Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up. | Transplantation proceedings 20090501 |
| Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. | Transplantation proceedings 20090501 |
| Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients. | Transplantation proceedings 20090501 |
| Posttransplant proteinuria associated with everolimus. | Transplantation proceedings 20090501 |
| The impact of everolimus on renal function in maintenance liver transplantation. | Transplantation proceedings 20090501 |
| Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience. | Transplantation proceedings 20090501 |
| Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. | JACC. Cardiovascular interventions 20090501 |
| The pharmacology of mTOR inhibition. | Science signaling 20090421 |
| Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. | Blood 20090402 |
| Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. | Biochemical pharmacology 20090401 |
| Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. | Anti-cancer drugs 20090401 |
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. | The oncologist 20090401 |
| Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. | Molecular cancer therapeutics 20090401 |
| Right adrenal metastases of hepatocarcinoma after liver transplantation: case report and literature review. | Transplantation proceedings 20090401 |
| mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. | Expert review of molecular diagnostics 20090401 |
| RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20090401 |
| A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. | Lancet (London, England) 20090314 |
| Nanoscale mechanical measurement determination of the glass transition temperature of poly(lactic acid)/everolimus coated stents in air and dissolution media. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090302 |
| A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. | Annals of hematology 20090301 |
| A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). | Journal of neuro-oncology 20090301 |
| Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. | Transplant international : official journal of the European Society for Organ Transplantation 20090301 |
| Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts. | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20090301 |
| mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090301 |
| Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. | Cancer chemotherapy and pharmacology 20090301 |
| Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime. | Transplantation 20090227 |
| AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | Circulation 20090210 |
| Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. | The Journal of pharmacology and experimental therapeutics 20090201 |
| Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. | Therapeutic drug monitoring 20090201 |
| Novel role of the CXC chemokine receptor 3 in inflammatory response to arterial injury: involvement of mTORC1. | Circulation research 20090130 |
| Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. | British journal of cancer 20090127 |
| Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. | British journal of cancer 20090127 |
| Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110 |
| Glycemic control in patients with insulinoma treated with everolimus. | The New England journal of medicine 20090108 |
| Minimization protocols in pancreas transplantation. | Transplant international : official journal of the European Society for Organ Transplantation 20090101 |
| Calcineurin-inhibitor minimization protocols in heart transplantation. | Transplant international : official journal of the European Society for Organ Transplantation 20090101 |
| Assessment with optical coherence tomography of a new strategy for bifurcational lesion treatment: the Tryton Side-Branch Stent. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20090101 |
| San Antonio Breast Cancer Symposium. | The Lancet. Oncology 20090101 |
| Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. | Pathology international 20090101 |
| Everolimus-associated pneumonitis in 3 heart transplant recipients. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20090101 |
| Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101 |
| Cyclosporin A, but not everolimus, inhibits DNA repair in human fibroblasts and lymphoblasts. | International journal of clinical pharmacology and therapeutics 20090101 |
| [Topics in mTOR pathway and its inhibitors]. | Bulletin du cancer 20090101 |
| Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report. | Transplantation proceedings 20090101 |
| Everolimus in liver and lung transplantation. | Drugs of today (Barcelona, Spain : 1998) 20090101 |
| Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20090101 |
| A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. | Nature protocols 20090101 |
| Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. | Drug metabolism and pharmacokinetics 20090101 |
| Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. | BMC cancer 20090101 |
| The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. | Annals of transplantation 20090101 |
| Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. | Clinical drug investigation 20090101 |
| Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. | Molecular cancer 20090101 |
| Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. | Transplantation proceedings 20090101 |
| De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. | Transplantation proceedings 20090101 |
| Conversion to everolimus in kidney transplant recipients with decreased renal function. | Transplantation proceedings 20090101 |
| Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. | Transplantation proceedings 20090101 |
| Indications and management of everolimus after liver transplantation. | Transplantation proceedings 20090101 |
| Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. | Transplantation proceedings 20090101 |
| Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. | Transplantation proceedings 20090101 |
| Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. | Transplantation proceedings 20090101 |
| FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. | Clinical transplantation 20090101 |
| Chronic allograft nephropathy--a clinical syndrome: early detection and the potential role of proliferation signal inhibitors. | Clinical transplantation 20090101 |
| Can proliferation signal inhibitor-induced Tregs really reflect transplantation tolerance in clinical solid organ transplantation? | International reviews of immunology 20090101 |
| Effects of everolimus on cytokines, oxidative stress, and renal histology in ischemia-reperfusion injury of the kidney. | Renal failure 20090101 |
| [Pneumonitis caused by sirolimus: improvement after switching to everolimus]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101 |
| Adherence must always be considered: is everolimus really ineffective as a treatment for atopic dermatitis? | The Journal of dermatological treatment 20090101 |
| Severe atopic dermatitis treated with everolimus. | The Journal of dermatological treatment 20090101 |
| Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program. | Vascular health and risk management 20090101 |
| Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent. | The American journal of cardiology 20081215 |
| Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature. | Pediatric transplantation 20081201 |
| Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. | Leukemia 20081201 |
| Laryngeal transplantation in the setting of cancer: a rat model. | The Laryngoscope 20081201 |
| Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. | Expert opinion on investigational drugs 20081201 |
| Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20081201 |
| Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20081201 |
| [Everolimus (RAD001) and solid tumours: a 2008 summary]. | Bulletin du cancer 20081201 |
| Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine. | Transplantation proceedings 20081201 |
| Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. | Journal of the American College of Cardiology 20081111 |
| A mathematical model for predicting drug release from a biodurable drug-eluting stent coating. | Journal of biomedical materials research. Part A 20081101 |
| Differential promotion of hematopoietic chimerism and inhibition of alloreactive T cell proliferation by combinations of anti-CD40Ligand, anti-LFA-1, everolimus, and deoxyspergualin. | Transplant immunology 20081101 |
| Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20081101 |
| Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. | The Annals of pharmacotherapy 20081101 |
| Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. | Journal of hypertension 20081101 |
| Systemic therapy for metastatic renal cell carcinoma. | The Urologic clinics of North America 20081101 |
| [67-year-old patient with speech disorder and dysphagia]. | Deutsche medizinische Wochenschrift (1946) 20081101 |
| Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. | Transplantation proceedings 20081101 |
| Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy. | Transplantation proceedings 20081101 |
| Use of everolimus in de novo renal recipients: initial experience in the Greek population. | Transplantation proceedings 20081101 |
| Metabolic changes following conversion from an anticalcineurin-based therapy to an everolimus-based one: a single-center experience. | Transplantation proceedings 20081101 |
| One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. | Transplantation 20081027 |
| Severe everolimus-associated pneumonitis in a renal transplant recipient. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001 |
| Bioabsorbable drug-eluting stents: the future of coronary angioplasty? | Nature clinical practice. Cardiovascular medicine 20081001 |
| Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty. | Ophthalmic research 20081001 |
| Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study. | Journal of interventional cardiology 20081001 |
| Novel drugs for renal cell carcinoma. | Expert opinion on investigational drugs 20081001 |
| Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. | American heart journal 20081001 |
| Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20081001 |
| Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. | Transplantation proceedings 20081001 |
| Out with the old, in with the new: immunosuppression minimization in children. | Current opinion in organ transplantation 20081001 |
| Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080910 |
| Major treatment improvements encourage kidney cancer researchers to seek further gains. | Journal of the National Cancer Institute 20080903 |
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. | The Journal of clinical investigation 20080902 |
| Positive reasons for publishing negative findings. | The American journal of gastroenterology 20080901 |
| A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. | The American journal of gastroenterology 20080901 |
| Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. | Cancer biology & therapy 20080901 |
| Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080901 |
| mTOR inhibitors and unilateral edema. | Revista espanola de cardiologia 20080901 |
| Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience. | Transplantation proceedings 20080901 |
| NCCN Task Force Report: mTOR inhibition in solid tumors. | Journal of the National Comprehensive Cancer Network : JNCCN 20080901 |
| Clinical investigations in T-cell and NK-cell non-Hodgkin lymphoma. | Clinical advances in hematology & oncology : H&O 20080901 |
| Progression-free survival as endpoint in metastatic RCC? | Lancet (London, England) 20080809 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. | Lancet (London, England) 20080809 |
| Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. | Annals of the rheumatic diseases 20080801 |
| The macrolide everolimus forms an unusual metabolite in animals and humans: identification of a phosphocholine ester. | Drug metabolism and disposition: the biological fate of chemicals 20080801 |
| In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. | Anti-cancer drugs 20080801 |
| Corneal permeation studies of everolimus microemulsion. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20080801 |
| Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: results of a 6-month pilot study. | Clinical nephrology 20080801 |
| Endothelial cell recovery between comparator polymer-based drug-eluting stents. | Journal of the American College of Cardiology 20080729 |
| Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. | Transplantation 20080727 |
| Clinical trials probe new therapies for some difficult-to-treat cancers. | JAMA 20080723 |
| Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. | Molecular pharmacology 20080701 |
| Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. | Autophagy 20080701 |
| Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20080701 |
| Everolimus-related pulmonary toxicity in heart transplant recipients. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20080701 |
| Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs. | The Journal of heart valve disease 20080701 |
| PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080615 |
| Everolimus for refractory Crohn's disease: a case report. | Inflammatory bowel diseases 20080601 |
| Simultaneous quantification of cyclosporine, tacrolimus, sirolimus and everolimus in whole blood by liquid chromatography-electrospray mass spectrometry. | Clinical biochemistry 20080601 |
| RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. | The Prostate 20080601 |
| Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. | Cytokine 20080601 |
| Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. | Pediatric transplantation 20080601 |
| Drug reactions - new observations. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20080601 |
| Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. | Expert opinion on drug metabolism & toxicology 20080601 |
| Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20080521 |
| Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. | Atherosclerosis 20080501 |
| Coronary aneurysm formation in a patient early after everolimus-eluting stent implantation. | The Journal of invasive cardiology 20080501 |
| Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Molecular cancer therapeutics 20080501 |
| Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. | JAMA 20080423 |
| Next-generation drug-eluting stents: a spirited step forward or more of the same. | JAMA 20080423 |
| Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005. | Nephrology (Carlton, Vic.) 20080401 |
| Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401 |
| Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401 |
| Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401 |
| Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001). | Annales d'endocrinologie 20080401 |
| Conversion therapy to everolimus in renal transplant recipients: results after one year. | Transplantation proceedings 20080401 |
| Drug essentials mTOR inhibitors. | Oncology (Williston Park, N.Y.) 20080401 |
| Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | Transplantation 20080327 |
| Biodegradable drug-eluting stents: promises and pitfalls. | Lancet (London, England) 20080315 |
| A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. | Lancet (London, England) 20080315 |
| Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. | British journal of cancer 20080311 |
| Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. | Molecular therapy : the journal of the American Society of Gene Therapy 20080301 |
| A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080201 |
| Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. | Therapeutic drug monitoring 20080201 |
| Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080201 |
| Pulmonary complications of novel antineoplastic agents for solid tumors. | Chest 20080201 |
| Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20080201 |
| Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20080201 |
| The potential role of mTOR inhibitors in non-small cell lung cancer. | The oncologist 20080201 |
| Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher). | Minerva cardioangiologica 20080201 |
| Future stent drug delivery systems. | Minerva cardioangiologica 20080201 |
| Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). | Vascular health and risk management 20080201 |
| Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. | Cancer research 20080115 |
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. | Blood 20080101 |
| Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. | Neuroendocrinology 20080101 |
| The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. | European journal of cancer (Oxford, England : 1990) 20080101 |
| Huge right atrial thrombus 6 years after heart transplantation. | The Annals of thoracic surgery 20080101 |
| San Antonio Breast Cancer Symposium. | The Lancet. Oncology 20080101 |
| A sensitive high-throughput HPLC assay for simultaneous determination of everolimus and clobetasol propionate. | Journal of chromatographic science 20080101 |
| The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. | Nephron. Experimental nephrology 20080101 |
| Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. | Clinical transplantation 20080101 |
| mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells. | Journal of vascular research 20080101 |
| Drug-eluting stents - what should be improved? | Annals of medicine 20080101 |
| Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients. | International journal of immunopathology and pharmacology 20080101 |
| Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty. | Endothelium : journal of endothelial cell research 20080101 |
| Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations. | Journal of clinical laboratory analysis 20080101 |
| Mammalian target of rapamycin as a target in hematological malignancies. | Current problems in cancer 20080101 |
| Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results. | Transplantation proceedings 20080101 |
| The South African branch of the Crossroads Institute celebrates it second birthday. | Cardiovascular journal of Africa 20080101 |
| Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. | Annals of transplantation 20080101 |
| Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation. | International journal of immunopathology and pharmacology 20080101 |
| Signaling inhibitors in metastatic renal cell carcinoma. | Cancer journal (Sudbury, Mass.) 20080101 |
| Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. | Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20080101 |
| Failure of systematic error detection with internal quality control program. | Annals of clinical and laboratory science 20080101 |
| [Chronic allograft dysfunction: role of immunosuppressive treatment]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101 |
| [ASCO 2008. Bevacizumab in advanced renal carcinoma]. | Tumori 20080101 |
| Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. | Drug metabolism and pharmacokinetics 20080101 |
| mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. | Anticancer research 20080101 |
| A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. | Transplantation 20071215 |
| The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. | Transplantation 20071215 |
| Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. | Therapeutic drug monitoring 20071201 |
| [mTOR signal pathway and its inhibitors in antitumor therapy: a review]. | Ai zheng = Aizheng = Chinese journal of cancer 20071201 |
| Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. | Transplantation proceedings 20071201 |
| Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation. | Transplantation proceedings 20071201 |
| Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report. | Transplantation proceedings 20071201 |
| Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071101 |
| Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20071101 |
| A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. | Clinical lung cancer 20071101 |
| Phase I study of everolimus in pediatric patients with refractory solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020 |
| Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20071001 |
| Rapamycin: something old, something new, sometimes borrowed and now renewed. | Clinical pharmacology and therapeutics 20071001 |
| Polymeric stents: degradable but strong. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20071001 |
| Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. | Therapeutic drug monitoring 20071001 |
| Internal standard selection for the high-performance liquid chromatography tandem mass spectroscopy assay of everolimus in blood. | Therapeutic drug monitoring 20071001 |
| Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071001 |
| Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. | Transplantation 20070927 |
| The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. | Molecular cancer therapeutics 20070901 |
| Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. | Haematologica 20070901 |
| Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070901 |
| mTOR inhibitors: do they help preserve renal function? | Transplantation proceedings 20070901 |
| Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. | Transplantation proceedings 20070901 |
| Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. | Transplantation proceedings 20070901 |
| Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. | Transplantation proceedings 20070901 |
| mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study. | Transplantation proceedings 20070901 |
| Sirolimus in renal transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070901 |
| Sunitinib, sorafenib and mTOR inhibitors in renal cancer. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901 |
| [3/3 Inhibitors of mTOR (sirolimus and everolimus)]. | Soins; la revue de reference infirmiere 20070901 |
| Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. | Cancer gene therapy 20070801 |
| Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. | Cancer 20070801 |
| Modulation of cholesterol homeostasis by antiproliferative drugs in human pterygium fibroblasts. | Investigative ophthalmology & visual science 20070801 |
| Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070801 |
| mTOR in tuberous sclerosis and other neurological disorders. | Epilepsia 20070801 |
| Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. | Annals of oncology : official journal of the European Society for Medical Oncology 20070801 |
| The biology behind mTOR inhibition in sarcoma. | The oncologist 20070801 |
| Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. | Expert review of anticancer therapy 20070801 |
| RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070715 |
| The role of mTOR inhibitors for treatment of sarcomas. | Current oncology reports 20070701 |
| Uneventful thoracic healing with everolimus after aortic valve replacement. | The Annals of thoracic surgery 20070701 |
| Interleukin-17 and airway inflammation: a longitudinal airway biopsy study after lung transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070701 |
| Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070701 |
| Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. | Journal of pharmacokinetics and pharmacodynamics 20070601 |
| mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. | International immunopharmacology 20070601 |
| Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. | Journal of mass spectrometry : JMS 20070601 |
| Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070601 |
| Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070601 |
| Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation. | Clinica chimica acta; international journal of clinical chemistry 20070501 |
| An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20070501 |
| Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. | Pediatric transplantation 20070501 |
| Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. | Clinical and experimental immunology 20070501 |
| Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501 |
| Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501 |
| Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501 |
| Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501 |
| Clinical development of mTOR inhibitors: a focus on lymphoma. | Reviews on recent clinical trials 20070501 |
| Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. | Blood 20070415 |
| A HPLC-mass spectrometric method suitable for the therapeutic drug monitoring of everolimus. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. | Transplant international : official journal of the European Society for Organ Transplantation 20070401 |
| PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. | International immunology 20070401 |
| Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070401 |
| Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. | Transplantation proceedings 20070401 |
| Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation. | Transplantation proceedings 20070401 |
| RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. | Cancer research 20070315 |
| Modeling of degradation and drug release from a biodegradable stent coating. | Journal of biomedical materials research. Part A 20070301 |
| Proliferation signal inhibitors in cardiac transplantation. | Current opinion in cardiology 20070301 |
| New advances in antirejection therapy. | Current opinion in cardiology 20070301 |
| Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. | American journal of obstetrics and gynecology 20070301 |
| Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070301 |
| Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. | Transplantation 20070227 |
| Selective clearance of macrophages in atherosclerotic plaques by autophagy. | Journal of the American College of Cardiology 20070213 |
| Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. | Leukemia 20070201 |
| Severe psoriasis treated with a new macrolide: everolimus. | The British journal of dermatology 20070201 |
| Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. | Clinical pharmacology and therapeutics 20070201 |
| Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. | Molecular cancer therapeutics 20070201 |
| Determination of everolimus in whole blood using the Abbott IMx sirolimus microparticle enzyme immunoassay. | Clinical biochemistry 20070101 |
| First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070101 |
| Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells. | Acta haematologica 20070101 |
| No robust conclusions to be drawn from clinical trials in the absence of an adequate control group. | Transplant international : official journal of the European Society for Organ Transplantation 20070101 |
| 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. | Transplant international : official journal of the European Society for Organ Transplantation 20070101 |
| XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. | Expert review of medical devices 20070101 |
| Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. | Autophagy 20070101 |
| The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. | Neuroendocrinology 20070101 |
| Do the benefits outweigh the risks with drug-eluting stents? | Scandinavian cardiovascular journal : SCJ 20070101 |
| Immunosuppression on the horizon. | Heart failure clinics 20070101 |
| Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. | Kidney & blood pressure research 20070101 |
| Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. | Clinical transplantation 20070101 |
| Immunosuppression for lung transplantation: evidence to date. | Drugs 20070101 |
| Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure. | Transplantation proceedings 20070101 |
| Possible role of everolimus in improving renal function in long-term heart transplantation. | Transplantation proceedings 20070101 |
| Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy? | European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20070101 |
| RAD inhibition of sarcoma growth: implications for laryngeal transplantation. | American journal of otolaryngology 20070101 |
| Newer stents: looking at the horizon. | Indian heart journal 20070101 |
| Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation. | International immunopharmacology 20061220 |
| Everolimus interferes with healing of experimental intestinal anastomoses. | Transplantation 20061215 |
| Targeting von Hippel-Lindau pathway in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061215 |
| Everolimus drug interactions: application of a classification system for clinical decision making. | Biopharmaceutics & drug disposition 20061201 |
| Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. | The Journal of biological chemistry 20061201 |
| Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. | Clinical biochemistry 20061201 |
| Differential effects of immunosuppressive drugs on T-cell motility. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20061201 |
| Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. | Cancer research 20061201 |
| The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. | Therapeutic drug monitoring 20061201 |
| Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. | Transplantation proceedings 20061201 |
| Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function. | Transplantation proceedings 20061201 |
| Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20061101 |
| Inclusion of MPA and in a rapid multi-drug LC-tandem mass spectrometric method for simultaneous determination of immunosuppressants. | Clinica chimica acta; international journal of clinical chemistry 20061101 |
| Everolimus and mTOR inhibitors in liver transplantation: opening the 'box'. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20061101 |
| A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. | Chemistry & biology 20061101 |
| Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. | Clinical colorectal cancer 20061101 |
| Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. | Cancer research 20061015 |
| Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20061001 |
| Calcineurin-inhibitor induced pain syndrome after organ transplantation. | Kidney international 20061001 |
| The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. | Molecular cancer therapeutics 20061001 |
| Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. | Clinical breast cancer 20061001 |
| Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. | Transplantation proceedings 20061001 |
| Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. | Transplantation proceedings 20061001 |
| Fibroblasts isolated from human pterygia exhibit altered lipid metabolism characteristics. | Experimental eye research 20060901 |
| Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. | British journal of haematology 20060901 |
| Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060901 |
| Therapeutic targets: MTOR and related pathways. | Cancer biology & therapy 20060901 |
| Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. | Transplantation proceedings 20060901 |
| Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen. | Transplantation proceedings 20060901 |
| Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). | The American journal of cardiology 20060815 |
| Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. | Gynecologic oncology 20060801 |
| Everolimus alters imatinib blood partition in favour of the erythrocyte. | The Journal of pharmacy and pharmacology 20060801 |
| Sensitive, high throughput HPLC-MS/MS method with on-line sample clean-up for everolimus measurement. | Therapeutic drug monitoring 20060801 |
| Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. | Clinical biochemistry 20060701 |
| Experimental efficacy of an everolimus eluting cobalt chromium stent. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20060701 |
| Everolimus: an immunosuppressive agent in transplantation. | Expert opinion on pharmacotherapy 20060701 |
| Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Everolimus in clinical practice--renal transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Conversion to everolimus in maintenance patients--current clinical strategies. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. | Transplant immunology 20060601 |
| Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. | Anti-cancer drugs 20060601 |
| Targeting mTOR for cancer treatment. | Current opinion in investigational drugs (London, England : 2000) 20060601 |
| Switching immunosuppressive drugs in kidney transplant recipients: 'show me the evidence'. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20060601 |
| Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). | The Laryngoscope 20060501 |
| Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. | Molecular cancer therapeutics 20060501 |
| Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature. | Leukemia & lymphoma 20060501 |
| Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression. | Transplantation proceedings 20060501 |
| Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. | The Cochrane database of systematic reviews 20060419 |
| Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20060401 |
| Resolution of sirolimus-induced pneumonitis after conversion to everolimus. | Transplantation proceedings 20060401 |
| Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. | Transplantation proceedings 20060401 |
| Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. | Transplantation proceedings 20060401 |
| Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. | Seminars in oncology 20060401 |
| New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. | Circulation 20060314 |
| Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. | Clinica chimica acta; international journal of clinical chemistry 20060201 |
| Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20060201 |
| Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060101 |
| Pulsed immunosuppression with everolimus and anti-alphabeta T-cell receptor: laryngeal allograft preservation at six months. | The Annals of otology, rhinology, and laryngology 20060101 |
| Everolimus: a review of its use in renal and cardiac transplantation. | Drugs 20060101 |
| Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens. | International journal of immunopathology and pharmacology 20060101 |
| Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. | Cardiovascular revascularization medicine : including molecular interventions 20060101 |
| Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20060101 |
| Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro. | World journal of gastroenterology 20051228 |
| In smooth muscle, FK506-binding protein modulates IP3 receptor-evoked Ca2+ release by mTOR and calcineurin. | Journal of cell science 20051201 |
| Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20051201 |
| Technology Insight: an overview of research in drug-eluting stents. | Nature clinical practice. Cardiovascular medicine 20051201 |
| Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. | Transplantation proceedings 20051201 |
| Late acute cardiac allograft rejection: new therapeutic options? | Transplantation proceedings 20051201 |
| Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. | Therapeutic drug monitoring 20051201 |
| Mammalian target of rapamycin as a therapeutic target in leukemia. | Current molecular medicine 20051101 |
| Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. | Transplantation 20051015 |
| [Everolimus]. | Deutsche medizinische Wochenschrift (1946) 20051007 |
| Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. | Leukemia 20051001 |
| Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. | Leukemia 20051001 |
| Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20051001 |
| The role of therapeutic monitoring of everolimus in solid organ transplantation. | Therapeutic drug monitoring 20051001 |
| Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. | British journal of clinical pharmacology 20051001 |
| Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates. | Toxicology 20050915 |
| A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. | Blood 20050901 |
| Analysis of exposure-response relationship in everolimus-cyclosporine combination regimen. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050901 |
| Therapeutic drug monitoring for everolimus in heart transplant recipients: flawed model or a model for future use? | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050901 |
| Immune cells in a heterotopic lamb-to-pig bronchial xenograft model. | Transplant international : official journal of the European Society for Organ Transplantation 20050901 |
| Simultaneous measurement of sirolimus and everolimus in whole blood by HPLC with ultraviolet detection. | Clinical chemistry 20050901 |
| Enhanced radiation damage of tumor vasculature by mTOR inhibitors. | Oncogene 20050818 |
| Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney. | British journal of pharmacology 20050801 |
| RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. | Cancer research 20050801 |
| Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. | Transplantation 20050727 |
| Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050715 |
| Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. | Journal of clinical pharmacology 20050701 |
| Everolimus alters the bronchoalveolar lavage and endobronchial biopsy immunologic profile post-human lung transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050601 |
| Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican). | Transplantation 20050515 |
| Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. | Transplantation 20050515 |
| Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. | Transplantation 20050515 |
| Clinical experience with everolimus (Certican): optimizing dose and tolerability. | Transplantation 20050515 |
| Clinical experience with everolimus (Certican) in elderly recipients: the 'old-for-old' concept. | Transplantation 20050515 |
| Clinical experience with everolimus (Certican) in young renal transplant recipients. | Transplantation 20050515 |
| Clinical experience with everolimus (Certican): a summary. | Transplantation 20050515 |
| Blood concentrations of everolimus are markedly increased by ketoconazole. | Journal of clinical pharmacology 20050501 |
| Replicating oncolytic virus therapeutics - Third International Meeting. | IDrugs : the investigational drugs journal 20050501 |
| Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. | Academic radiology 20050501 |
| Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. | Transplantation 20050427 |
| Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients. | European journal of medical research 20050420 |
| Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. | International journal of cardiology 20050408 |
| Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. | Clinical transplantation 20050401 |
| Certican (Everolimus) in heart transplantation: from clinical trial to clinical experience. Proceedings of a meeting, Vienna, Austria, September 9, 2004. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20050401 |
| From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20050401 |
| Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20050401 |
| Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20050401 |
| Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20050401 |
| Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20050401 |
| Validation of a practical liquid chomatography with ultraviolet detection method for quantification of whole-blood everolimus in a clinical TDM laboratory. | Therapeutic drug monitoring 20050401 |
| Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. | Transplantation proceedings 20050401 |
| The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. | Cell 20050325 |
| Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050301 |
| Effect of multiple-dose erythromycin on everolimus pharmacokinetics. | European journal of clinical pharmacology 20050301 |
| A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. | Transplantation proceedings 20050301 |
| High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225 |
| Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. | Clinical transplantation 20050201 |
| Use of everolimus-eluting stent with a bioresorbable polymer coating for treatment of recurrent in-stent restenosis. | The Journal of invasive cardiology 20050201 |
| Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. | Clinical nephrology 20050201 |
| Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). | The American journal of cardiology 20050101 |
| Coping with rejection: immunosuppressants and organ transplantation. | Drug discovery today 20050101 |
| [New immunodepressant drugs for the prevention and control of kidney transplant rejection]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20050101 |
| Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. | Transplantation proceedings 20050101 |
| Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. | Circulation 20041221 |
| Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies? | Journal of interventional cardiology 20041201 |
| Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. | Journal of interventional cardiology 20041201 |
| Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20041201 |
| Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. | International journal of clinical pharmacology and therapeutics 20041201 |
| [16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics]. | Bulletin du cancer 20041201 |
| Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. | Transplantation 20041127 |
| Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. | Transplantation 20041115 |
| Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis. | The Journal of pathology 20041101 |
| Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. | Apoptosis : an international journal on programmed cell death 20041101 |
| Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. | Bone 20041101 |
| Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20041001 |
| Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. | British journal of pharmacology 20041001 |
| Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. | Therapeutic drug monitoring 20041001 |
| [When are drug-eluting stents effective? A critical analysis of the presently available data]. | Zeitschrift fur Kardiologie 20040901 |
| Drug-eluting stents: is it the beginning of the end for coronary artery bypass surgery? | Chinese medical journal 20040901 |
| Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice. | Transplantation 20040815 |
| Everolimus-induced drug fever after heart transplantation. | Transplantation 20040727 |
| New immunosuppressant class not without serious concerns. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040615 |
| mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. | Nature medicine 20040601 |
| TORward AKTually useful mouse models. | Nature medicine 20040601 |
| Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication. | Progress in transplantation (Aliso Viejo, Calif.) 20040601 |
| Future immunosuppressive agents in solid-organ transplantation. | Progress in transplantation (Aliso Viejo, Calif.) 20040601 |
| Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. | Circulation 20040511 |
| How many grails do we need? | Circulation 20040511 |
| Everolimus stent proves effective. | Circulation 20040511 |
| Optimizing the immunosuppressive regimen in heart transplantation. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20040501 |
| Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. | Transplant international : official journal of the European Society for Organ Transplantation 20040501 |
| ['Active' endoprosthesis with in situ release of an antimitotic or cytostatic drug: a revolution that cannot do without thought]. | Annales de cardiologie et d'angeiologie 20040501 |
| Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20040401 |
| Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. | Transplantation 20040327 |
| The evolving experience using everolimus in clinical transplantation. | Transplantation proceedings 20040301 |
| Experience with everolimus. | Transplantation proceedings 20040301 |
| The promise of C2, Simulect, and Certican in heart transplantation. | Transplantation proceedings 20040301 |
| Promise of Neoral C2, basiliximab, and everolimus in lung transplantation. | Transplantation proceedings 20040301 |
| Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. | Herz 20040301 |
| Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. | Current opinion in cardiology 20040301 |
| Molecule of the month. Everolimus. | Drug news & perspectives 20040301 |
| Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. | Cancer 20040215 |
| Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant? | Expert opinion on investigational drugs 20040201 |
| Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction. | Drugs of today (Barcelona, Spain : 1998) 20040201 |
| Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | Transplantation 20040127 |
| Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. | Cancer research 20040101 |
| Clinical pharmacokinetics of everolimus. | Clinical pharmacokinetics 20040101 |
| Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. | Digestive diseases and sciences 20040101 |
| Everolimus. | Drugs 20040101 |
| New immunosuppressive strategies in renal transplant recipients. | Journal of nephrology 20040101 |
| Everolimus for stent-based intracoronary applications. | Reviews in cardiovascular medicine 20040101 |
| [Everolimus: immunosuppression with antilymphoproliferative therapy]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20040101 |
| The pleiotropic effects of mTor inhibitors. | Journal of nephrology 20040101 |
| Everolimus in cardiac-transplant recipients. | The New England journal of medicine 20031204 |
| Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20031201 |
| Current immunosuppressive agents: efficacy, side effects, and utilization. | Pediatric clinics of North America 20031201 |
| Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. | Transplantation 20031027 |
| Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20031001 |
| Cardiac-allograft vasculopathy. | The New England journal of medicine 20030828 |
| Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. | The New England journal of medicine 20030828 |
| Apoptosis and treatment of chronic allograft nephropathy with everolimus. | Transplantation 20030815 |
| Survival of acute myeloid leukemia cells requires PI3 kinase activation. | Blood 20030801 |
| Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. | The American journal of pathology 20030701 |
| The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20030701 |
| Everolimus in pediatric de nova renal transplant patients. | Transplantation 20030627 |
| Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. | Clinical transplantation 20030601 |
| Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. | Transplantation 20030527 |
| Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20030501 |
| Macrophage labeling by SPIO as an early marker of allograft chronic rejection in a rat model of kidney transplantation. | Magnetic resonance in medicine 20030301 |
| Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. | Journal of clinical pharmacology 20030201 |
| Synergistic effects of RAD and Neoral in inhibition of host-vs.-graft and graft-vs.-host immune responses in rat small-bowel transplantation. | Microsurgery 20030101 |
| Review of the proliferation inhibitor everolimus. | Expert opinion on investigational drugs 20021201 |
| Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. | Bone marrow transplantation 20021201 |
| Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. | Transplantation proceedings 20021201 |
| [To further improve transplantation results]. | Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20021201 |
| Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. | Current opinion in nephrology and hypertension 20021101 |
| Systemic drug therapy for restenosis: 'déjà vu all over again'. | Circulation 20021029 |
| Oral everolimus inhibits in-stent neointimal growth. | Circulation 20021029 |
| Clinical development of mammalian target of rapamycin inhibitors. | Hematology/oncology clinics of North America 20021001 |
| Everolimus (Certican) in combination with neoral in pediatric renal transplant recipients: interim analysis after 3 months. | Transplantation proceedings 20020901 |
| Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients. | Transplantation proceedings 20020901 |
| Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020605 |
| Effect of rifampin on apparent clearance of everolimus. | The Annals of pharmacotherapy 20020601 |
| Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. | Clinical chemistry 20020601 |
| Influence of a novel rapamycin analogon SDZ RAD on endothelial tissue factor and adhesion molecule expression. | Transplantation proceedings 20020601 |
| The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. | The European respiratory journal 20020601 |
| Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. | Pediatric transplantation 20020401 |
| Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. | Transplantation 20020327 |
| The future role of target of rapamycin inhibitors in renal transplantation. | Current opinion in urology 20020301 |
| Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). | Clinical chemistry and laboratory medicine 20020301 |
| Early clinical experience with a novel rapamycin derivative. | Therapeutic drug monitoring 20020201 |
| Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. | Journal of clinical pharmacology 20020201 |
| Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. | Pharmacotherapy 20020201 |
| Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. | Current opinion in investigational drugs (London, England : 2000) 20020201 |
| Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. | Cornea 20020101 |
| Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. | Journal of clinical pharmacology 20020101 |
| Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. | Clinical pharmacology and therapeutics 20011101 |
| Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001 |
| Efficacy of SDZ RAD compared with CsA monotherapyand combined Rad/FTY720 treatment in a murine cardiac allotransplantation model. | Transplant immunology 20011001 |
| Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts. | Transplantation 20010927 |
| Immune cells and immunosuppression in a porcine bronchial model of obliterative bronchiolitis. | Transplantation 20010927 |
| Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. | Clinical pharmacology and therapeutics 20010901 |
| [Focus on Islets of Langerhans transplantation]. | Presse medicale (Paris, France : 1983) 20010901 |
| [mTOR and FTY 720 inhibitors]. | Presse medicale (Paris, France : 1983) 20010901 |
| [Immunosuppression, ongoing clinical trials]. | Presse medicale (Paris, France : 1983) 20010901 |
| Everolimus. Novartis. | Current opinion in investigational drugs (London, England : 2000) 20010901 |
| Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs. | Journal of immunological methods 20010801 |
| In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. | Journal of mass spectrometry : JMS 20010801 |
| Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. | British journal of pharmacology 20010701 |
| The effect of different immunosuppressants on alloantigen dependent and independent factors involved in the development of chronic rejection in an animal model. | Annals of the Royal College of Surgeons of England 20010701 |
| Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. | Journal of medicinal chemistry 20010607 |
| A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor. | The Journal of pharmacology and experimental therapeutics 20010601 |
| mTOR inhibitors: an overview. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20010601 |
| RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. | Transplantation 20010527 |
| RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection. | Transplantation proceedings 20010501 |
| FTY-720 is efficacious in monkey kidney transplantation. | Transplantation proceedings 20010501 |
| 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. | American journal of respiratory and critical care medicine 20010201 |
| Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. | Transplantation 20010115 |
| Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. | Clinical pharmacology and therapeutics 20010101 |
| Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. | Transplantation proceedings 20010101 |
| Donor pretreatment of grafts from marginal donors improves long-term graft outcome. | Transplantation proceedings 20010101 |
| High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood. | Rapid communications in mass spectrometry : RCM 20010101 |
| The evolving role of tor inhibitors for individualizing posttransplant immunosuppression. | Transplantation proceedings 20010101 |
| The role of Certican (everolimus, rad) in the many pathways of chronic rejection. | Transplantation proceedings 20010101 |
| Effect of ERL080A, RAD, and Neoral on hamster-to-rat heart xenograft survival. | Transplantation proceedings 20010101 |
| A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. | Transplantation 19991027 |
| Chemical modification of rapamycin: the discovery of SDZ RAD. | Transplantation proceedings 19980801 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.